TickerFacts.

Kiniksa Pharmaceuticals International, plc (KNSA): Revenue

Annual figures by period end, from SEC filings.

$677.56M
Year ended 2025-12-31
$754.04M
Trailing 12 months to 2026-03-31
+45.5%
3-year compound annual growth
2021-12-31: $38.54M2022-12-31: $220.18M2023-12-31: $270.26M2024-12-31: $423.24M2025-12-31: $677.56M$677.56M
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$677.56M+60.1%2026-02-24, From 2025-01-01
2024-12-31$423.24M+56.6%2026-02-24, From 2024-01-01
2023-12-31$270.26M+22.7%2026-02-24, From 2023-01-01
2022-12-31$220.18M+471.2%2025-02-25, From 2022-01-01
2021-12-31$38.54Mn/a2024-02-28, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Kiniksa Pharmaceuticals International, plc (KNSA)2025-12-31$677.56M+60.1%
Ultragenyx Pharmaceutical Inc. (RARE)2025-12-31$673.00M+20.2%
Supernus Pharmaceuticals, Inc. (SUPN)2025-12-31$718.95M+8.6%
Axsome Therapeutics, Inc. (AXSM)2025-12-31$638.50M+65.5%
Amphastar Pharmaceuticals, Inc. (AMPH)2025-12-31$719.89M-1.7%
Pacira BioSciences, Inc. (PCRX)2025-12-31$726.41M+3.6%
Emergent BioSolutions Inc. (EBS)2025-12-31$742.90M-28.8%
TG Therapeutics, Inc. (TGTX)2025-12-31$616.29M+87.3%
Opko Health, Inc. (OPK)2025-12-31$606.88M-14.9%

Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗